Physician profile
Danielle M Sigelko
NPI 1821322090
$981.40
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $166.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $202.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $176.36 | 2019-2020 | |
| Amgen INC. | $76.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $74.80 | 2019-2020 | |
| Lilly USA, LLC | $62.49 | 2019-2020 | |
| Novo Nordisk INC | $57.90 | 2019 | |
| Glaxosmithkline, LLC. | $51.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $26.66 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.18 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.55 | 2019 | |
| Sanofi Pasteur INC. | $18.43 | 2019 | |
| Allergan, INC. | $18.27 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $16.57 | 2019 | |
| Circassia INC. | $15.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.38 | 2019 | |
| Dexcom, INC. | $12.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Sigelko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.